Drug Patent Expiration and Exclusivity
|Active Ingredient||Form||Dosage||Drug Type||Application||Product|
|EMEDASTINE DIFUMARATE||SOLUTION/DROPS; OPHTHALMIC||0.05%||RX||020706||001|
There are 1 patent(s) protecting ALCON’s EMADINE.
The last patent expires on 2013-12-08.
|US5441958||Ophthalmic compositions comprising emedastine and methods for their use
Topical ophthalmic compositions comprising 1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)-benzimidazole and its ophthalmically acceptable acid addition salts have been found to be useful in treating allergic conjunctivitis and related ailments.
Exclusivity is marketing rights granted by the FDA to the ALCON.
EMADINE ® (emedastine difumarate ophthalmic solution) 0.05% is a sterile ophthalmic solution containing emedastine, a relatively selective, H1-receptorantagonist for topical administration to the eyes. Emedastine difumarate is a white, crystalline, water-soluble…
View original post 390 more words